All articles
Industry TrendsJuly 20, 2026·2 min read

Decentralized and Hybrid Trials: What They Mean for Sites

DCTs were supposed to make sites obsolete. Instead, hybrid models are redefining the site’s job — and creating opportunities for the ones that adapt.

By Trialflow Team

The pandemic-era prediction that decentralized clinical trials (DCTs) would replace research sites has aged into something more interesting: hybrid trials where remote elements handle what they're good at, and sites handle the rest.

What's actually being decentralized

The elements that have durably moved remote are the ones patients hate traveling for: routine follow-up questionnaires (ePRO), medication shipment, wearable-based data collection, and some monitoring visits via telehealth. What stubbornly stays at sites: screening procedures, complex assessments, infusions, imaging, and — critically — the human relationship that drives retention.

What hybrid means operationally

For sites, hybrid trials shift the workload rather than shrinking it:

  • Fewer but heavier in-person visits. The visits that remain are the complex ones.
  • More asynchronous work. Chasing ePRO compliance, triaging device alerts, and telehealth check-ins don't fit neatly into a visit-based scheduling model.
  • Technology support becomes a site function. When a 74-year-old participant's study app won't sync, the site is the help desk. Budget for it in trial negotiations, because it's real time.

The recruitment angle

Hybrid designs widen the catchment area — a participant who'd never commit to weekly visits might accept four in-person visits a year. Sites that recruit beyond their traditional radius, and say so in feasibility responses, are winning studies on that basis. Remote consent and pre-screening also compress the funnel: a candidate can go from ad click to consented without a first drive to the site.

Positioning your site

Sponsors placing hybrid studies look for sites with demonstrated telehealth workflows, ePRO compliance management, and comfort supporting devices. None of this requires massive investment — it requires doing it once, documenting it, and putting it in the capabilities deck. The sites that treat hybrid as an expansion of their service area, not a threat to their model, are the ones growing through the transition.

Enrolling studies shouldn't be this hard

Trialflow gives research sites one platform for lead management, AI trial matching, and recruitment analytics.

Request a Demo